PhRMA names new leads on state advocacy, strategic alliances

WASHINGTON — The Pharmaceutical Research and Manufacturers of America has announced leadership changes to some of its advocacy efforts as longtime SVP advocacy Jeff Bond is set to retire. The organization named SVP Scott LaGanga as head of PhRMA state advocacy, assuming Bond’s responsibilities. Shannon Graham has been named SVP and will lead PhRMA’s advocacy and strategic alliances program. 

 

“Jeff’s retirement from PhRMA comes after a remarkable 40-year career where he has served as a tireless advocate and seen us through some of the toughest challenges our industry has ever faced,” PhRMA president and CEO Stephen Ubl said. “On behalf of our member companies and our entire staff, I want to thank Jeff for his tremendous commitment to PhRMA, our industry and the patients we serve.”

 

LaGanga assumes his new role after nearly 10 years at PhRMA, most recently leading its third-party stakeholder relations, which includes outreach to patient groups, health care providers, business leaders, organized labor, venture capital and academic institutions. He was formerly executive director and co-founder of Washington, D.C.-based advocacy organization dedicated to the protection of physical and intellectual property rights, the Property Rights Alliance, and worked for many years with Americans for Tax Reform. He is a member of the board of the Pharmaceutical Industry Labor Management Association.

 

“Scott has a proven track record of leading cross-disciplinary teams at the federal and state levels,” Ubl said. “I look forward to him leveraging this experience and the power of our state advocacy organization to lead us through some of the most important work we have to do.”

 

Graham rises to her new role after eight years managing the strategic development and implementation of PhRMA’s federal- and state-based initiatives. Prior to her current role with PhRMA, Graham was manager of state advocacy and alliance development for GlaxoSmithKline.

 

“Shannon’s proven ability to develop relationships and cultivate new partnerships with patient advocates and other health care groups makes her the perfect person to take on this new role,” Ubl said. “She leads a talented team that excels at one of PhRMA’s most critical functions.”